BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

664 related articles for article (PubMed ID: 26289956)

  • 1. Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000-12.
    Iqbal S; Shi J; Seib K; Lewis P; Moro PL; Woo EJ; Shimabukuro T; Orenstein WA
    Lancet Infect Dis; 2015 Oct; 15(10):1175-1182. PubMed ID: 26289956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine.
    Wattigney WA; Mootrey GT; Braun MM; Chen RT
    Pediatrics; 2001 May; 107(5):E83. PubMed ID: 11331733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
    Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.
    O'Ryan M; Bandyopadhyay AS; Villena R; Espinoza M; Novoa J; Weldon WC; Oberste MS; Self S; Borate BR; Asturias EJ; Clemens R; Orenstein W; Jimeno J; Rüttimann R; Costa Clemens SA;
    Lancet Infect Dis; 2015 Nov; 15(11):1273-82. PubMed ID: 26318714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China.
    Li R; Li CG; Li Y; Liu Y; Zhao H; Chen X; Kuriyakose S; Van Der Meeren O; Hardt K; Hezareh M; Roy-Ghanta S
    Vaccine; 2016 Mar; 34(12):1436-43. PubMed ID: 26873055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine.
    Daley MF; Yih WK; Glanz JM; Hambidge SJ; Narwaney KJ; Yin R; Li L; Nelson JC; Nordin JD; Klein NP; Jacobsen SJ; Weintraub E
    Vaccine; 2014 May; 32(25):3019-24. PubMed ID: 24699471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990-2013.
    Miller ER; Moro PL; Cano M; Lewis P; Bryant-Genevier M; Shimabukuro TT
    Vaccine; 2016 May; 34(25):2841-6. PubMed ID: 27087150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coverage estimates and patterns of inactivated poliovirus vaccine (IPV) use prior to and during the polio eradication endgame, Jinan City, China, 2010-2015.
    Chang C; Zhang J; Zhou J; Cao R; Song K; Liu C; Zhang X; Geng X; Liu X; Li C
    Hum Vaccin Immunother; 2016 Nov; 12(11):2749-2752. PubMed ID: 27437792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infant immunization with acellular pertussis vaccines in the United States: assessment of the first two years' data from the Vaccine Adverse Event Reporting System (VAERS).
    Braun MM; Mootrey GT; Salive ME; Chen RT; Ellenberg SS
    Pediatrics; 2000 Oct; 106(4):E51. PubMed ID: 11015546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine Adverse Event Reporting System (VAERS), 2005-2015.
    Haber P; Moro PL; Ng C; Lewis PW; Hibbs B; Schillie SF; Nelson NP; Li R; Stewart B; Cano MV
    Vaccine; 2018 Jan; 36(4):559-564. PubMed ID: 29241647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 1997 Jan; 46(RR-3):1-25. PubMed ID: 9026708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax(®)) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015.
    Moro PL; Winiecki S; Lewis P; Shimabukuro TT; Cano M
    Vaccine; 2015 Nov; 33(48):6684-8. PubMed ID: 26518405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the tolerability of an acellular pertussis-containing vaccine given as the fifth booster dose in differently primed children.
    Kemmeren JM; Timmer SS; van der Maas NA; de Melker HE
    Vaccine; 2011 Jun; 29(26):4373-7. PubMed ID: 21514347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
    Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
    Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial.
    Asturias EJ; Bandyopadhyay AS; Self S; Rivera L; Saez-Llorens X; Lopez E; Melgar M; Gaensbauer JT; Weldon WC; Oberste MS; Borate BR; Gast C; Clemens R; Orenstein W; O'Ryan G M; Jimeno J; Clemens SA; Ward J; Rüttimann R;
    Lancet; 2016 Jul; 388(10040):158-69. PubMed ID: 27212429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deaths Reported to the Vaccine Adverse Event Reporting System, United States, 1997-2013.
    Moro PL; Arana J; Cano M; Lewis P; Shimabukuro TT
    Clin Infect Dis; 2015 Sep; 61(6):980-7. PubMed ID: 26021988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introduction of Inactivated Poliovirus Vaccine and Impact on Vaccine-Associated Paralytic Poliomyelitis - Beijing, China, 2014-2016.
    Zhao D; Ma R; Zhou T; Yang F; Wu J; Sun H; Liu F; Lu L; Li X; Zuo S; Yao W; Yin J
    MMWR Morb Mortal Wkly Rep; 2017 Dec; 66(49):1357-1361. PubMed ID: 29240729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.
    Haber P; Moro PL; McNeil MM; Lewis P; Woo EJ; Hughes H; Shimabukuro TT
    Vaccine; 2014 Nov; 32(48):6499-504. PubMed ID: 25258101
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 34.